Dl-Aminoglutethimide en es it fr

Dl-Aminoglutethimide Brand names, Dl-Aminoglutethimide Analogs

Dl-Aminoglutethimide Brand Names Mixture

  • No information avaliable

Dl-Aminoglutethimide Chemical_Formula


Dl-Aminoglutethimide RX_link


Dl-Aminoglutethimide fda sheet

Dl-Aminoglutethimide FDA

Dl-Aminoglutethimide msds (material safety sheet)

Dl-Aminoglutethimide Synthesis Reference

Hoffmann, Urech, U.S. pat. 2,848,455 (1958 to Ciba)

Dl-Aminoglutethimide Molecular Weight

232.278 g/mol

Dl-Aminoglutethimide Melting Point

149-150 oC

Dl-Aminoglutethimide H2O Solubility

Practically insoluble in water

Dl-Aminoglutethimide State


Dl-Aminoglutethimide LogP


Dl-Aminoglutethimide Dosage Forms

Tablet (250 mg)

Dl-Aminoglutethimide Indication

For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.

Dl-Aminoglutethimide Pharmacology

Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.

Dl-Aminoglutethimide Absorption

Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.

Dl-Aminoglutethimide side effects and Toxicity

Oral LD50s (mg/kg): rats, 1800; dogs, >100. Intravenous LD50s (mg/kg): rats, 156; dogs, >100. Symptoms of overdose include respiratory depression, hypoventilation, hypotension, hypovolemic shock due to dehydration, somnolence, lethargy, coma, ataxia, dizziness, fatigue, nausea, and vomiting.

Dl-Aminoglutethimide Patient Information

Dl-Aminoglutethimide Organisms Affected

Humans and other mammals